Newly Diagnosed Multiple Myeloma: Discussions

ENG

Perseus, Iskia

ASH 2023

Important data on transplant-eligible NDMM

M. Merz, P. Sonneveld, B. Lipe, F. Schjesvold, H. Einsele, C. O. Landgren

ENG

SWOG S0777/S1211, EMN20, Rest

ASH 2023

Update on transplant-ineligible NDMM

M. Merz, P. Sonneveld, B. Lipe, F. Schjesvold, H. Einsele, C. O. Landgren

Newly Diagnosed Multiple Myeloma

ENG

Perseus, IsKia, IFM 2018-04

ASH 2023

Quatruplet therapy - the new standard in induction &…

Hermann Einsele, MD

ENG

Perseus

ASH 2023

Practice changing - Daratumumab before und after…

Maximilian Merz, MD

ENG

IsKia

ASH 2023

Isa-KRd - practice changing?

Katja Weisel, MD

ENG

IsKia

ASH 2023

CD38 antibodies - good in 1st line but bad in 2nd line?

Fredrik Schjesvold, MD

Newly Diagnosed Multiple Myeloma multilanguage

GER

IsKia

ASH 2023

Isa-KRd - practice changing?

Katja Weisel, MD

NOR

IsKia

ASH 2023

CD38-antistoffer - bra i førstelinje men ikke i…

Fredrik Schjesvold, MD

GER

Perseus, IsKia, IFM 2018-04

ASH 2023

Vierfachkombinationen - der neue Standard bei Induktion…

Hermann Einsele, MD

GER

Perseus

ASH 2023

Daratumumab vor und nach Transplantation neuer Standard

Maximilian Merz, MD

Relapsed Refractory Multiple Myeloma: Discussions

ENG

KarMMa-3

ASH 2023

The future of CAR T Cell treatment - I

M. Merz, P. Sonneveld, B. Lipe, F. Schjesvold, H. Einsele, C. O. Landgren

ENG

CARTITUDE-2

ASH 2023

The future of CAR T Cell treatment - II

M. Merz, P. Sonneveld, B. Lipe, F. Schjesvold, H. Einsele, C. O. Landgren

ENG

MonumenTAL-1

ASH 2023

Bispecific antibodies - update and outlook on treatment…

M. Merz, P. Sonneveld, B. Lipe, F. Schjesvold, H. Einsele, C. O. Landgren

Relapsed Refractory Multiple Myeloma

ENG

CARTITUDE-2

ASH 2023

cilta-cel in early lines

Maximilian Merz, MD

ENG

ASH 2023

New data on efficacy and safety of CAR T cells and…

Hermann Einsele, MD

ENG

ASH 2023

Early data on TriTac

Brea Lipe, MD

ENG

ASH 2023

Response predictors in immunotherapy

Brea Lipe, MD

ENG

KarMMa-3

ASH 2023

Survival data from KarMMa-3

Fredrik Schjesvold, MD

ENG

ASH 2023

Single-cell analysis of CAR T cells

Maximilian Merz, MD

Relapsed Refractory Multiple Myeloma multilanguage

GER

ASH 2023

Einzelzell-Analysen bei CAR-T-Zellen

Maximilian Merz, MD

NOR

KarMMa-3

ASH 2023

Overlevelsesdata fra KarMMa-3

Fredrik Schjesvold, MD

ENG

ASH 2023

CAR-T-Zellen und bispezifische Antikörper/TCEs: Neue…

Hermann Einsele, MD

GER

CARTITUDE-2

ASH 2023

cilta-cel in frühen Linien

Maximilian Merz, MD

MGUS & Smoldering Myeloma

ENG

ASH 2023

First whole genome sequencing trial with long-term FUP…

C. Ola Landgren, MD

ENG

CENTAURUS

ASH 2023

CENTAURUS: using single-drug Daratumumab in smoldering…

C. Ola Landgren, MD

ENG

Istopmm

ASH 2023

Are we ready for screening?

Brea Lipe, MD

ENG

Immuno-PRISM

ASH 2023

Are we preventing myeloma yet?

Brea Lipe, MD

MGUS & Smoldering Myeloma multilanguage

SWE

CENTAURUS

ASH 2023

CENTAURUS: using single-drug Daratumumab in smoldering…

C. Ola Landgren, MD

SWE

ASH 2023

First whole genome sequencing trial with long-term FUP…

C. Ola Landgren, MD

Follicular Lymphoma: Discussions

ENG

ELARA, CO41942, LYSA

ASH 2023

Updates for immunotherapy of follicular lymphoma

M. Dreyling, A. Marin-Niebla, M. Jerkeman, C. Thieblemont, T. Eyre, S. Ferrero

Follicular Lymphoma

ENG

ASH 2023

Bispecific antibodies in follicular lymphoma (1st line)

Martin Dreyling, MD

ENG

ASH 2023

Chemo-free combination for 1st line follicular lymphoma

Simone Ferrero, MD

ENG

ASH 2023

Cost-effectiveness analysis of Mosunetuzumab and CAR T…

Simone Ferrero, MD

ENG

Descart Registry Analysis from Lysa

ASH 2023

Real-world data of CAR T in relapsed follicular…

Simone Ferrero, MD

ENG

ELARA

ASH 2023

Long-term follow-up of ELARA study

Simone Ferrero, MD

ENG

TRANSCEND FL

ASH 2023

CAR T cells in follicular lymphoma (1st relapse)

Martin Dreyling, MD

Follicular Lymphoma multilanguage

ITA

ASH 2023

Una combinazione chemo-free per la prima linea del…

Simone Ferrero, MD

GER

TRANSCEND FL

ASH 2023

CAR-T-Zellen im follikulären Lymphom (erstes Rezidiv)

Martin Dreyling, MD

GER

ASH 2023

Bispezifische Antikörper im follikulären Lymphom (1st…

Martin Dreyling, MD

ITA

ASH 2023

Analisi costo-beneficio di mosunetuzumab vs CART nel…

Simone Ferrero, MD

ITA

Descart Registry Analysis from Lysa

ASH 2023

Data "real world" delle CART nel linfoma follicolare…

Simone Ferrero, MD

ITA

ELARA

ASH 2023

Follow-up a lungo termine dello studio ELARA

Simone Ferrero, MD

Indolent Lymphoma

ENG

Ilyad

ASH 2023

No efficacy of vitamin D in rituximab therapy

Martin Dreyling, MD

Indolent Lymphoma multilanguage

GER

Ilyad

ASH 2023

Keine Wirksamkeit von Vitamin D bei Rituximab-Therapie

Martin Dreyling, MD

Mantle Cell Lymphoma: Discussions

ASH 2023

New data for MCL - part I

M. Dreyling, A. Marin-Niebla, M. Jerkeman, C. Thieblemont, T. Eyre, S. Ferrero

ENG

Lyma and Lyma-101 comparison, Sympatico

ASH 2023

New data for MCL - part II

M. Dreyling, A. Marin-Niebla, M. Jerkeman, C. Thieblemont, T. Eyre, S. Ferrero

Mantle Cell Lymphoma

ENG

ASH 2023

Sequential use of R-bendamustine and ibrutinib?

Mats Jerkeman, MD

ENG

ASH 2023

TP53-mutant MCL - a new standard in 1st line?

Martin Dreyling, MD

ENG

Lyma and Lyma-101 comparison

ASH 2023

Is obinutuzumab superior to rituximab in MCL?

Mats Jerkeman, MD

ENG

ASH 2023

BOVEN: An effective MRD-guided strategy free of chemo…

Ana Marin Niebla, MD

ENG

Sympatico

ASH 2023

A new standard for R/R MCL?

Mats Jerkeman, MD

ENG

ASH 2023

Venetoclax added to RBAC significantly improves PFS in…

Ana Marin Niebla, MD

ENG

ASH 2023

Sobering results for bendamustine and venotoclax in MCL…

Martin Dreyling, MD

ENG

SYMPATICO

ASH 2023

Ibrutinib plus Venetoclax in R/R MCL - a new treatment…

Martin Dreyling, MD

ENG

ASH 2023

Adding Ara-C and lenalidomide to the standard RCHOP+RM…

Ana Marin Niebla, MD

ENG

SYMPATICO

ASH 2023

The SYMPATICO study confirms the synergy between…

Ana Marin Niebla, MD

Mantle Cell Lymphoma multilanguage

SWE

Sympatico

ASH 2023

Ny standardbehandling för recidiv av MCL?

Mats Jerkeman, MD

ESP

ASH 2023

BOVEN: Una estrategia sin quimio guiada por EMR,…

Ana Marin Niebla, MD

ESP

SYMPATICO

ASH 2023

El estudio SYMPATICO confirma la sinergia entre…

Ana Marin Niebla, MD

GER

SYMPATICO

ASH 2023

Ibrutinib plus Venetoclax beim rezidivierenden MCL -…

Martin Dreyling, MD

GER

ASH 2023

MCL mit TP53-Mutation: Neuer Standard in der Erstlinie?

Martin Dreyling, MD

ESP

ASH 2023

Añadir Ara-C y lenalidomida al estándar RCHOP+MR no…

Ana Marin Niebla, MD

SWE

Lyma and Lyma-101 comparison

ASH 2023

Vilken CD20-antikropp är att föredra vid MCL?

Mats Jerkeman, MD

ESP

ASH 2023

Venetoclax mejora significativamente la PFS de RBAC en…

Ana Marin Niebla, MD

SWE

ASH 2023

Sekventiell eller samtidig behandling med R-bendamustin…

Mats Jerkeman, MD

GER

ASH 2023

Ernüchternde Ergebnisse für Bendamustin und Venotoclax…

Martin Dreyling, MD

Chronic/Small Lymphocytic Leukemia: Discussions

ENG

GAIA/CLL13, FLAIR, ALPINE, ELEVATE-TN

ASH 2023

Highlights in chronic lymphocytic leukemia

M. Dreyling, A. Marin-Niebla, M. Jerkeman, C. Thieblemont, T. Eyre, S. Ferrero

Chronic/Small Lymphocytic Leukemia

ENG

ASH 2023

Sonrotoclax plus zanubrutinib in 1st line CLL

Toby Eyre, MD

ENG

BRUIN

ASH 2023

Pirtobrutinib in relapsed CLL

Toby Eyre, MD

ENG

FLAIR

ASH 2023

Ibrutinib plus venetoclax as MRD-guided treatment

Toby Eyre, MD

Hodgkin Lymphoma

ENG

ASH 2023

Bv-AVD in older patients

Martin Dreyling, MD

Hodgkin Lymphoma multilanguage

GER

ASH 2023

Nivo-AVD bei älteren Patienten besser als Bv-AVD

Martin Dreyling, MD

DLBCL: Discussions

ENG

ASH 2023

DLBCL - new treatment approaches and diagnostic…

M. Dreyling, A. Marin-Niebla, M. Jerkeman, C. Thieblemont, T. Eyre, S. Ferrero